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Chairman’s Welcome
Dear Colleagues and Friends,
The BFS Summer College is scheduled for 2 September 2008–5 September 2008, and will take place at the
newly refurbished Adelphi Hotel in Liverpool. This vibrant city is this year’s European Capital of Culture and
should provide an excellent setting for an exciting academic and social programme.
The College starts with a meeting primarily aimed at Persons Responsible and senior staff in fertility units. I
must stress that this day is open to all and, indeed, should be of value to all. Talks by international experts will
deal with current contentious issues such as PGD and management of unexplained infertility, with a view to
developing a consensus.
The main annual meeting takes as its theme ‘The uterus in reproduction’. The central role of implantation in
reproduction is clear, and our knowledge of mechanisms involved in successful implantation has developed
significantly in recent years. However, for the clinician involved in fertility, failure of fertility treatment at the
stage of implantation remains a challenging area. Patients, justifiably, demand answers and a modicum of
certainty, but providing these is made difficult by the diverse range of clinical practices and a poorly understood
evidence base. We aim to have an exciting programme with well-known speakers covering recent advances in the
basic science of implantation and approaches to recurrent implantation failure in the clinic. Special attention is
paid to uterine fibroids and their effects on reproduction, including a symposium on the role of uterine surgery
in the subfertile woman. We have space for oral and poster presentations of original research from all sections of
the membership, and I would encourage particularly younger members and nurses for whom there are a number
of prizes. The Summer College will conclude on 5 September 2008 with the Ethics Day, which is always
relevant and thought-provoking.
I hope that you will be able to attend the Summer College 2008 and both benefit from and contribute to its
wide-ranging and stimulating programme.
Raj Mathur
Chair BFS Meetings Subcommittee
Human Fertility, August 2008; 11(S1): 1
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BFS Summer College 2008
Schedule of Events
Tuesday, 2 September 2008
08:30–09:00 Registration
09:00–17:00 BFS Meeting for Persons Responsible and Senior Staff
18:00–19:30 BFS Summer College Welcome Reception
Wednesday, 3 September 2008
08:30–09:00 Registration
09:00–18:15 BFS Annual Summer Meeting–Day 1
18:15–19:15 BFS Summer College Posters, Cheese and Wine
19:30 Informal Social Evening Dinner, Jalons Restaurant (Ticket Only)
Thursday, 4 September 2008
08:00–08:30 Registration
08:30–17:05 BFS Annual Summer Meeting–Day 2
17:05–18:00 BFS Young Clinicians Forum
19:30 BFS Conference Dinner and Awards, Adelphi Hotel (Ticket Only)
Friday, 5 September 2008
08:30–09:00 Registration
09:00–17:00 BFS Ethics Meeting
ISSN 1464-7273 print/ISSN 1742-8149 online  British Fertility Society
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ABSTRACTS
Fertility 2008
BFS Summer College 2008
OC1: Do patients receiving donor sperm need evaluation
of their uterine cavity and fallopian tubes?
Tulay Karasu1, Ben Lavender1, Anne Hemingway2,
Geoffrey Trew1, & Stuart Lavery1
1IVF Unit, Hammersmith Hospital, London, United Kingdom, and
2Imaging, Imperial College Healthcare, London, United Kingdom
Introduction. In cases of infertility requiring the use of donor
sperm, there is a debate about whether investigations for uterine
and tubal pathology are routinely necessary, and if so which is the
investigation of choice. We wanted to find out whether assessment
of the uterine cavity and fallopian tubes with hysterosalpingogram
(HSG) detects a significant amount of pathology which could
affect treatment outcome.
Material & Methods. This is a retrospective study in a London
teaching hospital-assisted conception programme looking into the
investigations of women prior to their treatment with Donor sperm.
In the time period from January 2003 to November 2007, 162
women underwent assisted conception (IUI/IVF) Donor treatment
in our unit. The patients were identified from the embryology
database and data were collected from their case notes.
Results. One hundred and forty-nine women (92%) had an HSG
performed before starting their treatment. The HSG was normal
in 92 women (56.8%) and showed abnormalities in 57 women
(35.2%). Uterine pathology only was detected in 31 women
(20.8%) and tubal pathology only was described in six patients
(4%). Nineteen patients (12.8%) had uterine as well as tubal
pathology on HSG examination. HSG was abandoned in one
patient due to technical difficulties. Seventeen women (11.9%)
underwent laparoscopic surgery, and 10 of these women had
confirmed tubal pathology (7% in total), mainly hydrosalpinx.
Hysteroscopy was performed in 35 women (24.5%) with 25
women showing uterine abnormalities (17.5% in total). The main
findings were polyps in the uterine cavity.
Conclusions. 17.5% of the patients had confirmed uterine
abnormalities and 7% of the women demonstrated tubal pathol-
ogy. The findings of the HSG did influence further management
such as the decision to perform surgery or to proceed with IUI or
IVF. We therefore believe that evaluation of the uterine cavity and
tubes is justified in women before treatment with Donor sperm,
and in our own practice we use the HSG.
OC2: Correlation between number of eggs predicted
and actual eggs collected during IVF/ICSI stimulated
cycles: a prospective observational pilot study
Koli Chandra Reddy, Arianna D’angelo, Grace Jose,
Bebbie Jefferies, Lorraine Goucher, & Janet Evans
IVF Wales University Hospital of Wales, Cardiff, United Kingdom
Background. It is always difficult to predict accurately the number
of eggs to collect during an ART cycle only looking at the follicular
size and numbers on transvaginal scan on the day of hCG
injection. The accurate prediction is extremely important for
patients’ expectation and for the laboratory to prepare the culture
dishes for the day of the egg collection. The aim is to assess the
correlation between number and size of follicles reported by the
scan and actual number of oocytes collected.
Material & Method. Prospective observational data collection
between December 2007 and February 2008 (6 weeks) at the IVF
Wales Unit, University Hospital of Wales, Cardiff.
On the day of the oocyte retrieval, patients’ details including
demographic factors, stimulation regime, size and number of the
follicles on day 11, and when appropriate, day 14 of monitoring
were collected. The number of oocytes was predicted on the basis
of follicular mean size of  16 mm around the time of the trigger
injection. The actual number of eggs was collected on the day of
the procedure for each patient. Any difficulties encountered during
the procedure (i.e. high ovaries) were noted. Statistical analysis
performed using Microsoft Excel software.
Results. Twenty-six (26) women data were collected. Mean age
was 34 years (25–42), mean BMI was 26 (19–40), 92.4% were non-
smokers, 65.3% were primary subfertile, 65.3% had no previous
ART, 23% were PCO, 19.2% had endometriosis, 80.8% used
urinary hMG. According to the number of follicles plotted during
the scan, 57.6% had good response (6–14 follicles16 mm), 30.7%
had poor response (56 follicles 16 mm) and 11.5% had hyper
response (415 follicles 16 mm). On day of hCG injection, 35
follicles were between 12 and 13 mm, 47 follicles were between 14
and 15 mm and 151 were16 mm (total 233). The total number of
eggs predicted was 231, and the actual total number of eggs
collected was 217. 69.3% of the procedures were not difficult.
Conclusions. The mean follicular size measured by ultrasound on
the day of hCG of 12 mm over-estimates the number of
eggs collected by 7.3% (þ16 eggs). However, considering only
14 mm on same day underestimates by 8.7% (719 eggs). This
can be useful when counselling the patients and for the laboratory
organization before the egg collection.
OC3: Effect of pituitary desensitization on the early growing
follicular cohort estimated using Anti-Mullerian Hormone
Kannamannadiar Jayaprakasan, Bruce Campbell,
James Hopkisson, Jeanette Clewes, Ian Johnson, &
Nick Raine-Fenning
NURTURE, School of Human Development, University of
Nottingham, Nottingham, United Kingdom
Background. Although the decrease in FSH secondary to short-
term administration ofGnRHagonist during IVFdoes not affect the
number of ultrasonographically detected antral follicles, its effect on
the early growing follicle population, not evident on even high-
resolution ultrasound, is not known. The objective of this study was
to evaluate the effect of pituitary desensitization on the early growing
Human Fertility, August 2008; 11(S1): 3–13
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follicle population through assessment of serum anti-Mullerian
Hormone (AMH) concentration. Other markers of ovarian reserve,
basal FSH, LH, oestradiol, Inhibin-B and three-dimensional ultra-
sound ovarian parameters have also been assessed for comparison.
Methods. One-hundred and two subjects aged5 40 years with
FSH levels512 IU/l underwent venepuncture and transvaginal
ultrasound in the early follicular phase of the menstrual cycle and
after 14 days of downregulation usingGnRH agonists. Serum levels
of AMH and other markers of ovarian reserve measured during the
early follicular phase and thosemeasured followingdown-regulation
were compared using a paired students’ t-test for normally
distributed or Wilcoxon signed rank test and skewed data,
respectively. The study was approved by the National Health
Service research ethics committee, and written consent was
obtained prior to the enrolment of each subject.
Results. Although mean (+SD) AMH levels increased signifi-
cantly (P5 0.01) by about 28% (1.3+ 0.7–1.6+0.9 ng/ml), there
was a significant decline (P50.01) of about 40–50% in levels of
Inhibin-B (47.9+26.5 to 15.0+16.0 pg/ml), FSH (7.1+1.9 to
4.2+1.5 IU/l), LH (5.3+3.0 to 2.6+ 1.6 IU/l) and oestradiol
(156.5+ 66.3 to 64.3+45.3 pmol/l). Down-regulation treatment
was also associated with a decrease (P50.01) in mean ovarian
volume (6.5+ 2.0 to 5.6+ 2.2 cm3) and in ovarian blood flow
indices (vascularisation index: 7.5+ 4.3 to 6.1+5.0; flow index:
36.3+4.7 to 34.1+7.9 and vascular flow index: 2.9+ 1.8 to
2.3+1.8), but no difference was seen in the antral follicle count
(14.9+ 4.4 to 14.6+ 6.0).
Conclusion. Pituitary desensitization results in a significant
increase in AMH levels, which implies that either the secretion of
AMH by early growing follicles is enhanced or that the size of this
follicle cohort is increased. The number of antral follicles visualised
on ultrasound in the early follicular phase and at down-regulation
appears unchanged suggesting any effect is restricted to the smaller
‘selectable’ follicles.
OC4: Endometrial expression of follistatin and inhibin/
activin in women with implantation failure after IVF
Alka Prakash1, Elizabeth M. Tuckerman2, Susan Laird3,
Bolarinde Ola4, Tin C. Li3, & William L. Ledger5
1Addenbrookes Hospital, Cambridge, United Kingdom, 2Biomedical
Research Unit, Sheffield, United Kingdom, 3BRMC, Sheffield Hallam
University, Sheffield, United Kingdom, 4Academic Unit of
Reproductive and Developmental Medicine, University of Sheffield,
Sheffield, United Kingdom, and 5Royal Hallamshire Hospital,
Sheffield, United Kingdom
Introduction. The aim of the study was to assess the expression of
beta A and beta B subunit of inhibin/activin molecule and follistatin
in the endometrium of women with history of implantation failure
after IVF and compare it with a fertile control group.
Methods. This was a case–control study. Eleven women with
history of implantation failure were recruited from the implantation
failure clinic whereas seven women with history of proven fertility
were recruited as a control group. All women had daily measure-
ments of luteinising hormone (LH)until anLHsurgewas identified.
An endometrial biopsy sample was then taken at day LHþ 7. The
tissue obtained was dated using Noyes criteria and immunocyto-
chemistry using the ABC method was performed on paraffin
embedded sections to assess expression of beta A subunit, beta B
subunit and follistatin molecule expression in the endometrium.
Results. There was a trend for lower beta A stromal score in
women with implantation failure although this was not statistically
significant. The mean H score for glandular epithelial follistatin
expression was significantly lower in women with repeated IVF
failure as compared with the control group (P¼0.03).
Conclusion. The reduced expression of follistatin in the endome-
trial glandular compartment in women with implantation failure
did not translate into increased activin expression from the
endometrium. It may be hypothesized that other factors regulate
the activin follistatin pathway than currently known, and follistatin
appears to play a key role in implantation.
OC5: Placental dysfunction after infertility treatment
Jolly Joy1, Lee Armstrong2, Caroline Gannon2, Joy Ardill2,
Neil McClure1, & Inez Cooke1
1School of Medicine, Obstetrics & Gynaecology, Queen’s University
Belfast, Belfast, United Kingdom, and 2Royal Victoria Hospital,
Belfast, United Kingdom
Introduction. Artificial Reproductive Techniques (ART) and
conception following a period of untreated infertility (41 year)
are independently associated with increased pregnancy compli-
cations. Abnormal placentation identified by plasma markers,
placental macroscopic and/or microscopic changes may explain
some of these variances. The aim of this study was to compare
the gestational profile of biochemical markers of placental
function and placental histopathology of singleton pregnancies
conceived with ART and those conceived spontaneously either
with or without a period of infertility (41 year).
Methods. Non-smoking, age-matched primiparous women with
no significant medical history and with a singleton pregnancy were
recruited in three groups: ART (n¼ 38); natural conception
(n¼47); conception following untreated infertility (n¼21). Blood
samples were collected at five time points during the pregnancy
and tested for soluble fms like tyrosine kinase1 (sFlt1), Placental
Growth Factor (PLGF) and Leptin. Placentae were collected and
pathological examination was performed by one pathologist
blinded to the groups.
Results. ART group had significantly lower plasma levels of PLGF
at all time points compared with infertility and control groups
(P50.001). Infertility group had significantly higher levels of leptin
than ART or control group at all time points (P50.001). This did
not relate to their BMI. There were no significant differences in
sFlt1 levels between groups at the various time points. The mean
placental thickness was significantly higher in the ART group
(P¼ 0.02) with significantly more placental haematomas (P¼ 0.03)
compared with the control and infertility groups. There were no
differences in the incidence of abnormal placental shapes or cord
insertions. Lesions suggestive of a possible immunodysregulatory
response were more prevalent in the infertility group compared with
the other groups, but this did not achieve statistical significance.
Conclusion. Low plasma PLGF levels, increased placental thick-
ness and greater incidence of haematomas compared with the
other groups suggest abnormal placentation and/or abnormal
placental function in ART pregnancies.
OC6: Outcome of cryopreservation of biopsied blastocysts
after pre-implantation genetic diagnosis: a 2-year study
Tarek El-Toukhy, Yacoub Khalaf, Jan Grace, Arri Coomarasamy,
Eleanor Wharf, & Peter Braude
Guy’s and St. Thomas’ Hospital NHS Foundation Trust,
London, United Kingdom
Background. The ability to cryopreserve surplus embryos found
to be suitable for transfer after pre-implantation genetic diagnosis
(PGD) for serious genetic disease is particularly valuable due to
the complex nature and high cost of treatment.
Methods. Between February 2006 and March 2008, we per-
formed 21 PGD thaw cycles, in which 39 blastocysts resulting
from embryos biopsied on day 3 were thawed. Outcomes were
compared with 142 IVF/ICSI thaw cycles, in which 292 intact
blastocysts were thawed, using similar slow freezing and rapid
thawing laboratory protocols.
4 Fertility 2008
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Results. The mean age at cryopreservation was similar in the two
groups (32.4+4.7 vs. 33.5+3.7 years, P¼0.21). There were fewer
cryopreserved embryos available for thawing in the PGD cycles
(2.7+1.3 vs. 4.3+3 frozen embryos, P¼ 0.01). However, the
survival rate (87% vs. 84%, P¼0.73), mean number of embryos
replaced (1.5+0.5 vs. 1.6+0.48, P¼ 0.31), implantation rate (45%
vs. 27%, P¼ 0.06) and clinical pregnancy rate (43% vs. 34%,
P¼0.38) per thaw cycle were comparable in the PGD and IVF/ICSI
cycles, respectively. In addition, the pregnancy loss rate in the first
trimester was similar in the two groups (23.1% vs. 23.8%, P¼ 0.87).
Conclusion. Day 3 blastomere biopsy does not compromise
survival or implantation potential of cryopreserved blastocysts in
PGD cycles.
OC7: An exploration of the views and feelings of
women prior to embarking on a cycle of in vitro
fertilisation who have experienced a previous miscarriage
Jill Bulmer
Reproductive Medicine Unit, Leeds, United Kingdom
Introduction. Miscarriage is an overwhelming experience for any
woman, and a cruel blow for women who miscarry after years of
infertility treatment. Couples undergoing infertility treatments experi-
ence many and varied emotions. This report is an exploration of the
views and feelings of women prior to starting a cycle of in vitro
fertilisation (IVF) who have experienced a previous miscarriage. The
findings of this researchwill enable the care these women receive to be
focussed on their needs and the development of the service by better
understanding the women’s lived experience.
Methods. To address this research problem a qualitative approach
is used, and the study is based on phenomenological theory.
Ethical approval was obtained. Non-probability, purposive sam-
pling was employed to select the women to be interviewed. The
transcribed interviews were analysed using the methods described
by Burnard (1991). The categories are: treatment-related factors,
psychological factors, pregnancy-related anxiety and suggested
ways of improving care.
Results. The women reported concerns about previous assisted
conception treatments and shock, anxiety and stress following their
miscarriage. They expressed high levels of stress and anxiety about
starting treatment again because of the possibility of future loss and
grief. Suggested developments in care included: improved patient
information, better emotional support, incorporating a telephone
help line, support group and counselling and the provision of
miscarriage screening 2–3 weeks following their miscarriage.
Conclusion. The data obtained during this project support the
findings within the literature that both miscarriage and infertility
treatments cause increased levels of stress and anxiety. It confirms
previous findings that women experience high levels of stress, guilt,
grief and fears about their future childbearing. The women were
concerned about starting treatment again and needed support,
reassurance and information about treatment and their risk of another
miscarriage. They were extremely concerned about the possibility of
miscarriage, even before their pregnancy test was positive.
Reference
Burnard (1991). A method of analyzing interview transcripts of
qualitative research. Nurse Education Today, 11, 461–466.
OC8: The sources of emotional support used by couples/
individuals and the place for counselling throughout their
IVF treatment
Elspeth Graham, Maureen Porter, & Siladitya Bhattacharya
Department of Obstetrics & Gynaecology, University of Aberdeen,
Aberdeen, United Kingdom
IVF treatment is regarded as psychologically demanding. Because
of this, both the Human Fertilisation and Embryology Authority
(HFEA) and the National Institute for Clinical Excellence (NICE)
in Britain recommend that all treatment centres offer counselling.
However, research has shown that few couples access the
counselling provided.
Aims. The aims of this qualitative study were to identify the
psychological needs of individuals undergoing such treatment, the
perceived effectiveness of any support used and determine both
partners’ views on the use of counselling.
Methods. Both men and women in 16 couples were interviewed
individually following a failed embryo transfer. The results were
analysed using a grounded theory approach to categorise the data
and develop themes.
Results. It was found that individuals preferred initially to keep
their concerns around their infertility treatment private. Men and
women were found to use a variety of coping strategies
individually but had developed specific strategies for use as a
couple. Support from selected family and friends was valued but
couples found that coping with family distress was a disincentive
to continued family involvement. Individuals found reading
about the experiences of others via fertility chat rooms on the
internet both helpful and supportive. Printed information and
explanations of treatment plans from empathic and friendly staff
were appreciated but counselling was only considered to be
required when couples felt their situation threatened to over-
whelm them.
OC9: In vitro maturation: changing practice, setting
standards
Fiona Pringle
Oxford Fertility Unit, John Radcliffe Hospital, Oxford,
United Kingdom
The Oxford Fertility Unit made headline news in the national
press in September 2007 with reports of the first babies to be born
in the United Kingdom as a result of In Vitro Maturation (IVM)
techniques performed in a UK licensed centre. Although IVM is
not a new technique, fewer than 500 babies have been born
worldwide, and it has yet to become a mainstream treatment
offered by all IVF units in the UK.
The Oxford Fertility Unit was granted a licence by the Human
Fertilisation and Embryology Authority (HFEA) to carry out IVM
in January 2007, with the first oocyte collection taking place in
February 2007. Increasingly, patients are requesting treatment
options that involve minimal stimulation regimes or no stimulation
at all. To date, 29 cycles of IVM have been completed with an
average of 14 oocytes obtained per patient. The average age of
women undergoing this procedure is 33 years. 100% of women
have had embryos replaced. Positive pregnancy tests have been
reported in 34.5% of cycles with an implantation rate of 14% and a
clinical pregnancy rate of 24%.
The Oxford Fertility Unit’s experience to date demonstrates
that with appropriate patient selection, thorough staff training and
a great deal of hard work it is possible to offer a successful
alternative to standard IVF programmes.
OC10: Ectopic lesions from women with endometriosis
show structural and biochemical evidence of
delayed maturation
Carolyn Jones1,LucianoNardo1,PietroLitta2,&AsgerallyFazleabas3
1Department of Reproductive Medicine, University of Manchester,
Manchester, United Kingdom, 2Department of Gynecological Sciences
& Human Reproduction, University of Padua, Padua, Italy, and
3Department of Obstetrics & Gynecology, University of Illinois at
Chicago, Chicago, United States
Fertility 2008 5
H
um
 F
er
til
 (C
am
b) 
Do
wn
loa
de
d f
rom
 in
for
ma
he
alt
hc
are
.co
m 
by
 41
.21
5.7
0.2
14
 on
 03
/14
/11
Fo
r p
er
so
na
l u
se
 o
nl
y.
Following a study on the ultrastructure and lectin histochemistry
of eutopic and ectopic endometrium in a model of endometriosis
in the baboon (Jones et al., 2006), where initially a delay in
differentiation and expression of glycan markers of receptivity was
seen, followed in later disease by accelerated maturation, this study
aims to describe the ultrastructure and glycan expression in
ectopic lesions of women with endometriosis.
Ectopic biopsies from19womenwith proven endometriosiswere
fixed and processed into epoxy resin for electron microscopy and
lectin histochemical examinationusingDolichos biflorus agglutinin to
detectN-acetyl galactosamine sequences normally expressed in the
mid-to-late secretory eutopic endometrium. Biopsies of eutopic
endometrium from 15 healthy women were taken as controls. All
patients gave their consent for the study which was approved by the
Local Research Ethics Committee (Ref. 06/Q1407/173) and
Universities of Manchester and Padua, Italy.
Results showed that, at the ultrastructural level, lesions were
very heterogeneous between similarly dated specimens, and
showed little resemblance to their normal eutopic equivalents.
There was a notable dearth of glycogen accumulation in the
second half of the cycle and a complete absence of giant
mitochondria and nucleolar channel systems. Many cells lining
the lesions resembled mesothelium, and in two cases there was
evidence of a migratory cell population which invaded the stroma
to form new glandular structures. Almost all lesions failed to
express glycans bound by D. biflorus agglutinin at the expected
mid-to-late secretory phase of the cycle, unlike the controls.
These structural and biochemical findings suggest a failure in
differentiation of ectopic lesions which show significant differences
in architecture and function from the eutopic endometrium of
healthy women. Also, the presence of a migratory cell population
in some lesions may have important implications for the
aetiopathogenesis of endometriosis.
Reference
Jones, C. L. P., Denton, J., & Fazleabas, A. T. (2006).
Morphological and glycosylation changes associated with the
endometrium and ectopic lesions in a baboon model of
endometriosis. Human Reproduction, 21, 3068–3080.
OC11: Diabetes is associated with changes in key regulatory
and novel gene expression
Jason O’Neill1, Ishola Agbaje1, A. Platts2, Neil McClure1,
A. Atkinson2, Stephen Krawetz3, & Con Mallidis1
1School of Medicine, Obstetrics & Gynaecology, Queens University
Belfast, Belfast, Northern Ireland, United Kingdom, 2Regional Centre
for Endocrinology and Diabetes, Royal Victoria Hospital, Belfast,
Northern Ireland, United Kingdom, and 3Center for Molecular
Medicine & Genetics & Department of Obstetrics & Gynecology,
Wayne State University, Detroit, Michigan, United States
Introduction. It is becoming increasingly clear that far from being
innocuous, Diabetes Mellitus is associated with distinct aspects of
impaired male reproductive function. With the use of molecular
techniques, subtle, yet profound changes in glycation, metabolite
levels and sperm nuclear DNA status have all been recently
reported by our group. These are changes that have been shown to
be associated with decreased embryo quality, lower implantation
and increased miscarriage rates. The mechanisms responsible for
these perturbations and their consequences remain largely un-
known. Because of their transcriptional quiescence, sperm RNA
has been considered merely as an artefact. However, the evolution
of microarray technology has shown that this previously under-
estimated resource, acts as an accurate archive chronicling the
transcriptional activity involved in the production of the particular
sperm sample. We hypothesise that the expression of specific sperm
mRNAs is altered in the diabetic state, that these contribute to the
damaging changes we have previously found, and that ultimately
culminate in the decreased fertility seen in diabetic men.
Aim. By comparing mRNA expression profiles of sperm from
diabetic and normal fertile males, to identify which genes were
influenced and which mechanisms affected.
Methods. After informed consent was given, semen samples
from eight diabetic men were collected, assessed by standard
WHO criteria and spermatozoal RNA was then isolated. After
confirmation of quality, transcript profiles were obtained by
microarray analysis and compared with a database of profiles from
fertile men.
Results. The expression of numerous genes was significantly
altered in the sperm of diabetic men. Interestingly, many are
involved in DNA repair, ROS protection and oxidative stress. Of
note was the four-fold increase in the expression of spermatogen-
esis associated 20 (SPATA 20), a gene that has been localised to
the testis but whose function and/or influence remains unknown.
Conclusion. The extent of differences in mRNA expression levels of
important regulatory genes in the sperm of diabetic men, provides an
indication of the influence and the mechanisms by which Diabetes
Mellitus detrimentally affects male reproductive function.
OC12: Effect of coasting on quality and post-thaw
performance of cryopreserved embryos
Cruz Winston Justin & Luca Sabatini
Centre for Reproductive Medicine, St. Bartholemew’s Hospital,
London, United Kingdom
Introduction. Ovarian hyperstimulation is a potentially life-threa-
tening complication of assisted conception treatment. Coasting is
an effective alternative to cycle cancellation in women at high risk
of developing OHSS. Various studies have suggested a detrimental
effect of prolonged coasting (43 days) on oocyte and embryo
quality and implantation rates. We undertook this study to look at
the effect of coasting on embryos after cryopreserved-thawed
embryos.
Materials & Methods. The study is a retrospective case control
study. Sixty-five patients (39-IVF and 26 ICSI) underwent
coasting during the fresh cycle from over 5 years from 2001 to
2005. Sixty-five non-coasted controls were obtained during the
same period by matching for type of treatment, basal FSH, main
aetiology and body mass index. These 130 women underwent 154
frozen embryo replacement over 6 years between 2001 and 2006.
We analysed embryo survival, implantation, clinical pregnancy,
live birth and miscarriage rates in the two groups. A further
analysis was performed to see the effect of prolonged coasting on
cryopreserved embryo performance.
Results. There was no statistically significant difference in post-
thaw embryo survival rates (69% vs. 66.9%), implantation rates
(11.4% vs. 16%), clinical pregnancy rates (18% vs. 28%), live birth
rate (14.4 vs. 21.7%) and miscarriage rates (4% vs. 6.4%) between
the study and control groups. Failed thaw occurred in four cycles
in the study and two cycles in the control group. The quality of
embryos post-thaw was similar with 59.6% grade I embryos in the
coasted cryopreserved group compared with 58.6% in the non-
coasted group. On further analysis, there was a trend towards
poorer outcome with longer duration of coasting but this did not
reach statistical significance.
Conclusion. Coasting does not seem to significantly affect the
performance of cryopreserved embryos after thaw. However, there
seems to be a trend towards lower implantation rates in the
subgroup that underwent prolonged coasting. A much larger,
possibly prospective study will be required to further clarify this
issue. Our study contains larger numbers than the only published
study on this topic in the literature.
6 Fertility 2008
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OC13: Application of vitrification in the IVF laboratory
Lyndon Miles, Helen Morgan, Anna Storey, Angela Thropp,
Karen Campbell, Andrew Gordon, & Janet Evans
Cardiff and the Vale NHS Trust, Cardiff, United Kingdom
Introduction. Vitrification has the potential to become a very
valuable technique for human embryo cryopreservation, and
studies have demonstrated high rates of post-warming survival,
with healthy children resulting. This service evaluation presents
our survival rates and clinical outcomes of cryopreserved human
cleavage stage embryos during the first 6 months, following the
introduction of vitrification in our centre.
Material & Methods. Eight couples whose embryos had been
vitrified following informed consent, attended for frozen embryo
transfer. Embryos were vitrified 66–72 h post-insemination in
vitrification cooling solutions (Medicult). For thawing, D2 vitrified
embryos were warmed in vitrification warming solutions (Medi-
cult) and cultured for 24 h prior to ET. Vitrified D3 embryos were
warmed and transferred after at least 2 h of culture.
Results. Twenty-three embryos were vitrified and warmed for
these eight couples. Of those, 22 (96.9%) survived post-thaw.
Seven patients tested positive for pregnancy (87.5%) via urine
analysis after the transfer of two embryos each.
Of these seven pregnant patients, three (42.8%) resulted in a
biochemical pregnancy and one resulted in first trimester
miscarriage (14.2%). Three clinical pregnancies (2 singletons, 1
twin) were confirmed by the presence of foetal heart and are
ongoing at the time of submission. The resulting implantation rate
is therefore 25% (4/16).
Conclusions. Vitrification of D2 andD3 cleavage stage embryos on a
Cryoleaf is a very promising technique and has been easily
incorporated into our embryology laboratory. These early clinical
outcomes appear extremely promising and are notably higher than
past results with our traditional slow freeze methodologies. Further
follow up of the children needs to be undertaken to demonstrate
conclusively, the safety and clinical outcome of vitrification.
OC14: Expression and function of fibronectin in male
and female gametes during bovine fertilization in vitro
Mirjan Thys, Hans Nauwynck, Dominiek Maes,
Herman Favoreel, & Ann Van Soom
Faculty of Veterinary Medicine, Ghent University, Merelbeke, Belgium
Fibronectin (Fn) is a 440-kDa glycoprotein assumed to play a role
in sperm–egg interaction in human. Recently, it has been
demonstrated that Fn–when present during bovine in vitro
fertilization (IVF)–strongly inhibits sperm penetration and fertili-
zation. The present study was conducted (1) to determine which
IVF-steps were hindered by supplementation of 500 nM Fn
(including its effect on acrosome reaction and sperm motility), and
(2) to evaluate the expression of Fn and its integrin receptor
(a5b1) on male and female bovine gametes by means of indirect
immunofluorescence. The inhibition experiments indicated that
the main inhibitory effect of exogenously supplemented Fn was
located at the level of sperm–oolemma binding, with a (con-
current) effect on fusion. In accordance, we detected endogenous
Fn underneath the zona pellucida (at the level of the peri-vitelline
space) and a5 (subunit of Fn-receptor integrin a5b1) on the
oolemma of cumulus-denuded bovine oocytes. In addition, all
sampled bovine sperm cells displayed integrin a5. In the non-
treated and capacitated sperm fraction fluorescence at the rostral
sperm head was observed, whereas a fluorescent band at the
equatorial segment was noted in the acrosome reacted spermato-
zoa. The Fn molecules observed at the surface of non-treated and
capacitated spermatozoa seemed to disappear during acrosomal
reaction. Moreover, incubation of sperm cells with Alexa Fluor1
488-conjugated Fn also resulted in green fluorescence at the
equatorial segment. Combining these results, the inhibitory effect
of exogenously supplemented Fn seemed to be exerted on the
male gamete by binding to the exposed integrin a5b1 receptor after
acrosome reaction.
The presence of endogenous Fn underneath the zona pellucida
together with integrin a5 expression on the oolemma and the
acrosome reacted sperm cell surface, suggests interaction between
the Fn ligand and corresponding receptors on both (acrosome
reacted) sperm cell and oolemma, initiating sperm–egg binding.
Further research, identifying the effect of Fn binding to its integrin
a5b1 receptor on the intracellular signal transduction in male and
female gamete, is indispensable to elucidate the exact underlying
mechanism of interaction in order to validate our model and to
create a non-hormonal topical contraceptive – based on the
glycoprotein – in the future.
OC15: Direct health service costs of providing
assisted reproduction services in older women –
retrospective cross-sectional analysis
Abha Maheshwari, Graham Scotland, Alison McTavish,
Jacqueline Bell, Mark Hamilton, & Siladitya Bhattacharya
Department of Obstetrics & Gynaecology, University of Aberdeen,
Aberdeen, United Kingdom
Objective. To assess the total service costs incurred for each live-
birth achieved by older women undergoing IVF (in vitro fertiliza-
tion) in comparison with costs in younger women.
Design. Retrospective cross-sectional analysis.
Setting. IVF unit and maternity hospital in a tertiary care setting.
Participants. Women (1854) who underwent their first cycle of
IVF between 1997 and 2006. Of these, 341 (18.4 %) were under
30, 714 (38.5%) were 30–34; 640 (34.5 %) were 35–39 and 159
(8.6%) were 40 years or more.
Intervention. Bottom up costs was calculated for all interventions
in the IVF cycle. Early pregnancy and antenatal care costs were
obtained from NHS reference costs, ISD Scotland and local
departmental costs.
Main outcome measure. Cost per live birth in each age group.
Secondary outcome measures included cost per pregnancy and
cost per ongoing pregnancy.
Results. The mean cost per live birth (95% CI) in women
undergoing IVF at the age of 40 years and above was £37,824
(£26,911–£64,962), which is more than 2.5 times higher than those
aged 35–39 years (£17096 CI, £15,635-£18,937). The cost per
ongoing pregnancy was almost three times in women aged 40 and
above (£31,642; 95% CI, £21,241–£58,979) when compared with
women 35–39 years of age (£11,300 CI, £10,006–£12,938).
Conclusion. The cost of a live-birth following IVF rises signifi-
cantly at the age of 40 due to lower success rates. Most of the extra
cost is due to the IVF treatment, but some of it is due to higher
rates of early pregnancy loss.
OC16: Preimplantation genetic diagnosis for the prevention
of sickle cell disease: current trends and barriers to the
uptake of this service at Guy’s & St. Thomas NHS
Foundation Trust
Adeola Oyewo1, Tarek El-Toukhy2, & Eugene Oteng-Ntim2
1School of Medicine, King’s College London, London, United Kingdom,
and 2Guy’s & St. Thomas NHS Foundation Trust, London,
United Kingdom
Introduction. Sickle cell disease (SCD) is a potentially debilitating
haemoglobinopathy with increasing global incidence. In the
absence of effective curative therapies, preventative measures such
as preimplantation genetic diagnosis (PGD) are being employed to
reduce the incidence of the disorder. We describe the experience
Fertility 2008 7
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of the use of PGD for the prevention of SCD at a tertiary referral
PGD centre in a London teaching hospital and explore the
potential barriers to the wider uptake of this service.
Methods. A review of 16 PGD cycles performed for the
prevention of SCD in 12 couples at risk of having an affected
child was conducted. We also compared the outcome of PGD for
SCD and PGD for other autosomal recessive disorders (ARDs)
involving 122 cycles performed during the same period.
Results & Discussion. Two clinical pregnancies resulting in the
live birth of two unaffected children were reported for the 16 PGD
cycles carried out (clinical pregnancy rate of 13% per initiated
cycle). The data for PGD for the other ARDs showed a 25%
clinical pregnancy rate per initiated cycle. In addition, the
fertilisation rate was significantly higher in PGD for the other
ARDs (58%) compared with PGD for SCD (42%).
The uptake of this service at GSTT seems relatively low compared
with that of PGD for other monogenic disorders such as cystic
fibrosis. Possible explanations for this observation include a general
lack of awareness of the service among patients and local healthcare
providers and changing public attitudes to SCD due to enhanced
therapeutic management and coping strategies. In addition, the high
cost of the procedure coupled with a suboptimal success rate may
deter some at-risk couples from undergoing the procedure.
PGD for the prevention the birth of a child affected by SCD is
an established, viable treatment option for couples at risk of having
an affected child. However, barriers to uptake of this service need
to be fully addressed in order to ensure its availability to all couples
seeking to avoid having child affected with SCD.
OC17: Non-blastocyst selective single embryo transfer
does not reduce success rates in ART cycles in women
at high risk of multiple pregnancy
Nicholas Brook, Elaine Taylor, Caroline Lewis, Vivienne Hall,
Paul Curtis, & Andrew Riddle
Woking Nuffield Assisted Conception Unit, Woking, United Kingdom
Objective. To determine the clinical pregnancy rate (CPR) and
multiple pregnancy rate (MPR) in an ART programme following the
introduction of a new selective single embryo transfer protocol in a
selectedgroupofwomenundergoing fresh IVF/ICSI treatment cycles.
Population. 420 fresh ART cycles were performed between
October 2007 to April 2008 at the Assisted Conception Unit. Of
these, 41 women were eligible for the new protocol (35 years old
with excess embryos for freezing Group A) and 73 were excluded
(35 years old with no excess embryos for freezing Group B).
Methods. A new protocol was introduced following our HFEA
inspection 2007 and in line with the HFEA recommendation of an
MPR5 10% by 2010. This included a multidisciplinary approach
with patients being educated about the risks of multiple pregnancy
following the transfer of more than one embryo. The aim was to
transfer day 2 or 3 post-egg collection embryos without the need
for a change in our working pattern.
Main outcome measures CPR and MPR in eligible and non-
eligible women undergoing a fresh ART cycle.
Results. This selective single embryo transfer protocol resulted in
no difference in CPR 39% (16/41) in Group A versus 37% (27/73)
in Group B and a reduction in MPR from 30% (8/27) in Group B
to 0% (0/16) (P¼ 0.045) in Group A, with an overall MPR of 19%
(8/43) in Groups AþB for this age group.
Conclusion. Selective single embryo transfer in women with
prognostic features of 35 years and embryos available to freeze
should be mandatory. This protocol change can be introduced as
routine practice for all day 2 or 3 embryo transfers without the
need to change the clinic working pattern. As this is the age group
associated with the highest MPR this represents a significant step
towards achieving the HFEA goal of 510% MPR. We are in the
process of reviewing our protocols to reduce this further.
OC18: Egg donation before and after April 2005
Nikita Rawal, Maureen Richards, Andrew Drakeley, &
Rafit Gazvani
Liverpool Women’s Hospital, Liverpool, United Kingdom
Introduction. In April 2005, UK legislation was changed requiring
any donor of gametes or embryos used in the treatment of other
people to agree to the disclosure of their identity to any offspring
on reaching the age of 18.
Method. A retrospective study to find the effect of the change in
law on the egg donation programme in the UK’s largest fertility
unit at Liverpool Women’s Hospital.
Results. Forty-eight women donated eggs between April 2005
and April 2008, out of which 40 were known donations and 8
were anonymous donations. Eighteen women approached their
sisters to donate eggs and another 24 took help of their ‘friends’.
Five women donating eggs anonymously, donated to two
recipients.
Compared with 3 years before April 2005, 45 women donated
eggs, of which 15 were known donation and 30 were anonymous.
In the known donor group, 12 were sisters of women needing eggs,
one was sister-in-law and two were friends. Twenty women
donating eggs anonymously donated eggs to two recipients.
Currently, there are 86 women awaiting egg donation in our
unit. Considering the long waiting list and shortage of egg donors,
we have introduced egg-sharing programme in our unit since April
2008. Out of these 86 women, 40 are considering egg sharing.
Conclusion. Our results show the effect of change in law had on
an already restricted egg donation in UK. There is a need to
address this egg shortage by developing gamete donor recruitment
strategies.
P1: Effect of age, oestradiol levels and endometrial
thickness on determining success of frozen embryo transfers
Alfred Murage, Maybeth Jamieson, Robin Yates, Isabel Traynor,
Helen Lyall, & Scott Nelson
Glasgow Royal Infirmary, Glasgow, United Kingdom
Introduction. Frozen-thawed embryo transfer (FET) is a widely
used technique, with replacement of embryos during natural
menstrual cycles or in cycles constructed by exogenous steroids
having similar outcomes in many series. Multiple factors have been
proposed to have a positive influence on the success rate of FET,
including increased endometrial thickness, younger maternal age
and lower circulating oestradiol. The impact of these variables in
the context of constructed cycles, using GnRH agonists to
facilitate suppression of ovarian function prior to exogenous
steroid administration, is not known. The aim of this study was to
determine the predictive ability of these indices on clinical
outcomes.
Material & Methods. Charts of consecutive patients undergoing
constructed cycles of FET between February 2005 and September
2007 were reviewed. Construction of FET cycles was by mid-
luteal administration of depot GnRH agonist, with confirmation of
down-regulation 2–3 days after menstruation (serum oestra-
diol5 200 pmol/l and endometrial thickness55 mm), prior to
initiation of oestradiol valerate 6 mg/day. Transvaginal ultrasound
and biochemical monitoring of oestradiol were performed on days
D8 and D13, and progesterone 800 mg/day commenced on D13 if
endometrial thickness 6 mm. Patients failing to meet this
criterion were reassessed on day 18. Oestradiol was measured by
Immulite with intra- and inter-assay CVs of 8.6% and 9.3%,
respectively. Results are presented as mean+ standard deviation
or unadjusted median (interquartile range). Pearson correlations,
general linear models and stepwise logistic regression (P 0.15 for
inclusion of predictors) on log transformed variables were used to
assess relationships.
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Results. One hundred and fifty seven women with a median age
of 35 years (31–37 years), median oestradiol of 215 pmol/l (120–
305 pmol/l) and median endometrial thickness of 8.5 mm (7.2–
9.9 mm) underwent a constructed FET. Biochemical pregnancy
test was positive in 60 (38.2%), with 34 (21.6%) achieving a
clinical pregnancy as defined by positive fetal heart beat at 8 weeks
gestation. There were no significant differences in age, peak
oestradiol levels or endometrial thickness in those women
achieving a biochemical or clinical pregnancy. Despite this,
women with endometrial thickness  8 mm were significantly
more likely to achieve a clinical pregnancy (58 mm
13.1%;8 mm 27.1%; P¼0.04), although no differences were
observed for positive pregnancy tests (58 mm 32.8%; 8mm
41.7%; P¼0.26). Age and endometrial thickness were positively
associated (r¼ 0.18, P¼0.02), with circulating oestradiol not
related to endometrial thickness (r¼0.10, P¼0.19) or age
(r¼0.11, P¼ 0.18). Peak oestradiol (225 pmol/l) predicted
biochemical pregnancy better than age (P¼ 0.024) or endometrial
thickness (P¼0.049), however, it still performed relatively poorly
with an area under the ROC curve of 0.66 (95%CI 0.58–0.74),
sensitivity 65% (95% CI 51.6–76.9%) and specificity 64.9% (CI
54.6–74.4%). Age (AUC 0.56 (95%CI 0.48–0.64)), peak oestra-
diol ((AUC 0.55 (95%CI 0.47–0.63)) and endometrial thickness
(AUC 0.58 (95%CI 0.50–0.66)) all performed equally poorly in
the prediction of clinical pregnancy. Multivariate analysis demon-
strated that only peak oestradiol was independently associated with
a positive pregnancy test (contribution to variance 6.4%, positive,
P¼0.001), however, this relationship was not sustained for
prediction of clinical pregnancy.
Conclusions. We demonstrate that endometrial preparation with
oestrogen and progesterone after pituitary desensitisation with a
depot GnRH agonist is an effective protocol in women undergoing
FET, and achieves pregnancy rates similar to those reported
following fresh replacement cycles. Age does not affect the
pregnancy rate in women undergoing FET; similarly peak
oestradiol does not predict clinical pregnancy rates and is not a
useful additional test in women undergoing FET. The lack of
relationship between endometrial thickness and pregnancy out-
come questions the assignment of a lower limit prior to embryo
replacement.
P2: A randomized controlled trial of tubal flushing
for unexplained infertility
Nikita Rawal, Jaya Koyalli, Nabil Haddad, & Gian Abbott
Countess of Chester Hospital, Chester, United Kingdom
Background. There has been debate in the literature for over 40
years as to whether hydrotubation of the fallopian tubes enhances
fertility and whether this presumed therapeutic role is greater with
oil-soluble contrast media than with water-soluble contrast media
used for hysterosalpingography (HSG).
Aims. To evaluate the influence of the contrast material used in
HSG on subsequent reproductive success.
Method. A prospective, randomized, single blinded controlled
trial. Seventy-two couples with a diagnosis of primary or secondary
unexplained infertility were recruited in our trial. Computer-
generated random table were used and patients randomized before
HSG procedure. HSG was performed primarily as a diagnostic
procedure and was done within 10 days following menses. Thirty-
five couples were randomized to the water soluble group and
thirty-seven to oil soluble group. Four women were withdrawn
after randomization, as in two HSG could not be performed due to
technical problems and two women had bilateral blocked tubes.
Couples were followed up for 4 months and diagnosis of
pregnancy was confirmed by a trans vaginal ultrasound.
Results. Eight (21%) got pregnant in oil-soluble group and in
three of these women initial resistance was experienced during
tubal flushing. In water-soluble group five (14%) got pregnant but
two had early miscarriage.
Conclusion. Our study favours the effectiveness of tubal flushing
with oil soluble contrast media in increasing odds of pregnancy.
This could represent a simple, less invasive and economic
alternative to IVF for women with normal fallopian tubes.
P3: Salpingitis following oocyte aspiration and embryo
transfer – a case series
Joanna Ghigo & Muhammad Akhtar
Countess of Chester Hospital, Chester, Cheshire, United Kingdom
Introduction. Salpingitis following oocyte aspiration and
embryo transfer is a recognized rare complication of
in vitro fertilization therapy. The reported incidence is between
0.3 and 0.5%. We report two cases of pyosalpinges in a series of
more than 2000 transvaginal egg collection and embryo transfer
procedures.
Case reports. Two women undergoing in vitro fertilization
treatment for tubal factor infertility presented with pyosalpinges
at Countess of Chester Hospital.
Case 1, JW, developed severe abdominal pain 2 days after
frozen embryo transfer during natural cycle in vitro fertilization.
The pyosalpinx was initially drained percutaneously under
ultrasound guidance and resolved on intravenous antibiotic
therapy. Laparoscopic salpingectomy was carried out 10 weeks
later to remove a persisting hydrosalpinx.
Case 2, BL, had ultrasound guided transvaginal egg collection
under antibiotic cover. She presented 15 days post-embryo
transfer with abdominal distension and peritonitis. Laparatomy
revealed bilateral suppurative pyosalpinges and several loop
abscesses.
In both cases, high vaginal and endocervical swabs were taken
prior to initiation of treatment and were negative.
Discussion. The possible mechanisms for development of pyosal-
pinx following egg collection and embryo transfer include:
(a) Puncture of pelvic viscera at the time of egg collection.
(b) Rekindling of quiescent infection within the tubes from a
previous infection.
(c) Introduction of vaginal flora into the pelvic cavity during
oocyte aspiration.
(d) Introduction of organisms during embryo transfer.
In our unit, one dose of intravenous cefuroxime is given
prophylactically during egg collection but not at embryo transfer.
Conclusion. These cases highlight the risk of serious complica-
tions associated with in vitro fertilization therapy, emphasising the
need for appropriate counselling pre-treatment.
The possibility of severe pelvic infection following in vitro
fertilization therapy warrants consideration of prophylactic anti-
biotic cover.
P4: Costs and outcomes associated with mild in vitro
fertilisation or intracytoplasmic sperm injection
using recombinant follicle stimulating hormone
Amanda Holman1, William Ledger2, Debra Irwin3,
Pippa Anderson2, & Cas Weibinga4
1IMS Health Health Economics and Outcomes Research, London,
United Kingdom, 2Centre for Reproductive Medicine and Fertility,
Royal Hallamshire Hospital, Sheffield, United Kingdom,
3University of North Carolina, Chapel Hill, USA, and
44NV Organon, a part of Schering-Plough, Oss, Netherlands
Background & Objectives. In 2004, based on clinical evidence
and economic analysis, the National Institute for Health and
Fertility 2008 9
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Clinical Excellence (NICE) recommended that the NHS should
fund up to 3 cycles of in vitro fertilisation (IVF) or intracyto-
plasmic sperm injection (ICSI) for most women requiring
treatment. This recommendation was not fully implemented by
government, citing budget concerns, despite NICE finding IVF/
ICSI to be effective and cost-effective use of resources. This
study assesses cost and outcomes of IVF/ICSI in the UK, in
usual practice in the UK.
Methods. The study data utilised for this analysis is taken from
anonymised audit data held by a UK assisted conception unit
(ACU) unit. The data held in the ACU dataset covers women
receiving fresh cycles of IVF/ICSI from October 2001 to January
2006 in the unit which treats both National Health Service and
privately funded patients. Women undergoing IVF or ICSI who
were treated with one brand of recombinant follicle stimulating
hormone (rFSH) (Puregon1) within the ovarian stimulation
protocol were included in this analysis. Rates of ongoing
pregnancies per cycle and live birth rates were calculated. Drug
use was determined by linking ACU data to pharmacy
dispensing data. Costing for clinic procedures was based on a
prior financial audit of the centre. Costs were applied at UK
2007 prices.
Results. Data were available and analysed for 1418 IVF/ICSI
cycles undertaken by 1001 women. Mean duration of ovarian
stimulation was 9.1 days (95%CI: 9.0–9.3 days). The clinical
pregnancy rate/cycle was 36.4% (95%CI: 33.9–39%), the
ongoing pregnancy rate was 24.4% (95%CI: 22.2%–26.7%),
and the live birth rate was 22% (95%CI: 19.7–24.2%). The
average rFSH dose/cycle prescribed was 1855 units (SD: 561),
whereas the average dispensed dose/cycle was 1891 units
(SD: 540). The average cost of rFSH/cycle was £646 (SD:
219). Average cost/cycle for concomitant medications and
procedures was £159 (SD: 122) and £2,127 (SD 349),
respectively. The average total cost/cycle was £2,932 (SD:
422). The average cost per clinical pregnancy, cost per ongoing
pregnancy and cost per live birth were £8,058, £12,017 and
£13,326, respectively.
Conclusions. Although IVF/ICSI outcomes in this usual practice
setting were similar to UK averages the cost of rFSH/cycle was
lower than that estimated in the 2004 NICE guidelines. These
findings suggest that budgets for IVF/ICSI can be optimised taking
efficient drug delivery practices into account. However, the UK
government should increase funding overall to cover the recom-
mended levels of IVF/ICSI.
The study was funded by Organon, part of Schering-Plough
Corporation.
P5: Process mapping: investigation into annual number of
new patients required to successfully generate a patient
list for IVF/ICSI
Janet Evans, Katherine Maddocks, & Holly Kirwin
Cardiff Assisted Reproduction Unit, Cardiff, United Kingdom
Introduction. Not all patients referred to an infertility clinic
continue on to receive treatment, either due to eligibility or
personal circumstances. This study aims to follow NHS patient
numbers from a new patient clinic, to the waiting list, to those that
attend an evening information meeting and eventually receive
treatment. This will demonstrate where most dropouts occur and
the number of new patients required to generate a treatment list.
Material & Methods. Data from new patient clinics from April
2006 were obtained along with the number of patients who are on
the waiting list. As the duration of time on the waiting list is 1 year
(Welsh Assembly Government Criteria), numbers of patients who
attended evening clinics and received treatment the following year
were obtained until March 2007 to ensure follow up of the same
patients.
Results. As expected there were multiple dropouts at each stage.
707 patients attended new patient clinics between April 2006 and
March 2007, and of these 268 received treatment for IVF/ICSI,
giving a 37.9% uptake. Further analysis of the results will be
required to determine where these dropouts are occurring most
frequently.
Conclusions. There is an obvious discrepancy between the
numbers of patients presenting to new clinics who continue on
to receive IVF/ICSI treatment. This study shows in order to obtain
a patient list of 100 patients for IVF/ICSI treatment initially 264
patients will need to be seen. A prospective study will follow this
pilot to explore reasons for the findings.
P6: Is a reliable ovarian response predictable with AMH
and antral follicle count–can we reduce cycle cancellation
in poor responders irrespective of age? A retrospective
analysis
Abey Eapen
Midland Fertility Services, Aldridge, United Kingdom
Background. Controlled ovarian stimulation is still considered as
one of the advances in the field of infertility medicine. The dose of
stimulation medication is based on a number of factors grouped
together and called as the ovarian reserve tests or ovarian markers
for stimulation.
The most widely used endocrine marker for ovarian reserve is
the early follicular phase FSH level. Early follicular (basal) FSH
level has been shown to be an independent predictor of IVF
outcome. Even though there are other markers of ovarian
response, the reliability on any single determinant was of doubtful
significance.
The availability and application of so many tests of ovarian
reserve serves to illustrate the lack of a single reliable technique.
However, a recent addition to the list of promising candidates for
predicting ovarian response is anti-Mullerian hormone (AMH), a
member of the transforming growth factor-b super family. AMH is
produced in the ovary by granulosa cells of growing preantral and
small antral follicles.
Materials & Methods. This retrospective review included a total
of 138 patients classified as poor responders. All patients had
AMH measured on day 4–6 of their menstrual cycle along with a
transvaginal scan to assess the Antral follicle count. Patients who
underwent IVF/ICSI cycle between February 2006 and March
2008 were included in this study. The stimulation regimen and
dose was based on two ovarian markers.
Results. One hundred and twenty eight patients of this study
group underwent oocyte retrieval, and 120 of them underwent
embryo transfer.
Conclusion. AMH and antral follicle can be considered as best
two indicators for poor responders irrespective of age. No
significant association with the ovarian markers and the outcome
of IVF/ICSI treatment were evident.
P7: The introduction of anti Mullerian hormone in an IVF
setting
Asmita Patwardhan, Janet Evans, & Grace Jose
IVF Wales, Cardiff, United Kingdom
Background. Anti-Mullerian hormone (AMH) has shown to be
better predictor of ovarian reserve than follicle stimulating
hormone (FSH), antral follicle count, inhibinB and age. Dimin-
ishing ovarian reserve is a common occurrence in the IVF setting.
Prediction of response to IVF and optimizing the ovarian
stimulation regime to avoid cancellation is of great importance.
Also AMH may be useful in avoidance of cancellation due to
excess response (ovarian stimulation syndrome OHSS).
10 Fertility 2008
H
um
 F
er
til
 (C
am
b) 
Do
wn
loa
de
d f
rom
 in
for
ma
he
alt
hc
are
.co
m 
by
 41
.21
5.7
0.2
14
 on
 03
/14
/11
Fo
r p
er
so
na
l u
se
 o
nl
y.
Objective. To look at our initial experience of the introduction of
AMH levels prior to an IVF cycle and its correlation with outcome,
thus leading to the development of protocols for the determination
of appropriate dosage of gonadotrophin for individuals.
Design. Ongoing audit of the introduction of AMH and correla-
tion of levels with outcome since January 2008. Review of case
notes to correlate the ovarian response, clinical pregnancy rates
and OHSS.
Results. So far 60 patients have had AMH levels assessed.
Amongst the patients with AMH less than five, (33%) had a poor
response (less than five follicles). 10% had failed fertilization and
45% had a negative pregnancy test. Of those, seven patients with
high AMH levels (415), five (71%) had confirmed OHSS and all
needed cancellation of cycles or ‘freeze all’ embryos.
Conclusion. The introduction of AMH measurement in our unit
looks promising.Comparedwith FSH,AMHcan be done at any time
during the menstrual cycle, and therefore is convenient. In addition,
measurement of AMH has been demonstrated to be useful in
detecting those women at risk of a suboptimal outcome, in whom
gonadotrophin dosage may now be optimized. Protocol development
has been undertaken and will be implemented and audited.
P8: Application of vitrification in the IVF laboratory
Janet Evans & Debbie Jefferies
IVF Wales, Cardiff, United Kingdom
Introduction. Vitrification has the potential to become a very
valuable technique for human embryo cryopreservation, and
studies have demonstrated high rates of post-warming survival,
with healthy children resulting. This service evaluation presents
our survival rates and clinical outcomes of cryopreserved human
cleavage stage embryos during the first 6 months, following the
introduction of vitrification in our centre.
Material & Methods. Eight couples whose embryos had been
vitrified following informed consent, attended for frozen embryo
transfer. Embryos were vitrified 66–72 h post-insemination in
vitrification cooling solutions (Medicult). For thawing, D2
vitrified embryos were warmed in vitrification warming solutions
(Medicult) and cultured for 24 h prior to ET. Vitrified D3
embryos were warmed and transferred after at least 2 h of
culture.
Results. Twenty-three embryos were vitrified and warmed for
these eight couples. Of those, 22 (96.9%) survived post-thaw.
Seven patients tested positive for pregnancy (87.5%) via urine
analysis after the transfer of two embryos each.
Of these seven pregnant patients, three (42.8%) resulted in a
biochemical pregnancy and one resulted in first trimester
miscarriage (14.2%). Three clinical pregnancies (2 singletons, 1
twin) were confirmed by the presence of foetal heart and are
ongoing at the time of submission. The resulting implantation rate
is therefore 25% (4/16).
Conclusions. Vitrification of D2 and D3 cleavage stage embryos
on a Cryoleaf is a very promising technique and has been easily
incorporated into our embryology laboratory. These early clinical
outcomes appear extremely promising and are notably higher
than past results with our traditional slow freeze methodologies.
Further follow up of the children needs to be undertaken to
demonstrate conclusively, the safety and clinical outcome of
vitrification.
P9: High ongoing pregnancy rates with a new vitrification
medium after oocyte vitrification and thawing
Onder Coban1, Oguzhan Hacifazlioglu1, H. Ibrahim Tekin1,
Mustafa Bahceci2, & H. Nadir Ciray2
1OrtaDogu ve Balkanlar IVF Center, Magusa, Cyprus and
2Bahceci IVF Center, Istanbul, Turkey
Vitrification of oocytes is a relatively new method and its
superiority over slow freezing is under debate. More vitrification
media became commercially available compared with several years
ago. The present study reports outcome of cycles in which oocytes
were frozen and subsequently thawed (and transferred) with a
recently introduced vitrification media (SAGE Biofarma, Thorn-
bull). Metaphase II oocytes were frozen in SAGE Vitrification
Media at *3 h after retrieval immediately after denudation. The
vitrification procedure was performed according to the Kuwaya-
ma protocol (Kuwayama et al., 2005) using the Cryotop
technique in high security straws (CBS, Paris). The thawing
procedure has been performed as described previously (Kuwaya-
ma et al., 2005). In seven donor cycles, transfer embryos were
obtained from oocytes that have been vitrified and subsequently
thawed (Table 1). From 96 vitrified Metaphase II oocytes, 69
survived (% mean+SD; 69+18) and were subsequently
subjected to ICSI. The fertilization rate was 71+ 26 (%). All
cycles resulted in embryo transfer. The results have been
obtained in four transfers of whom three were positive and all
are currently ongoing (between 9 and 15 weeks). The implanta-
tion rate was 36% (4/11). These results showed that high ongoing
pregnancy rates can be obtained after vitrification and thawing of
oocytes in SAGE media. The survival rate can be improved after
an extended time period when the embryologists get experienced
and by reducing the number of oocytes that were subjected to
vitrification in each straw.
Reference
Kuwayama, M., Vajta, G., Kato, O., & Leibo, S. P. (2005). Highly
efficient vitrification method for cryopreservation of human
oocytes. Reproductive Biomedicine Online, 11, 300–308.
Table 1. Outcome of cycles in which embryos derived from vitrified and thawed oocytes were transferred.
ET cycle
Frozen
oocytes
Survived
oocytes
%
Survival
Two pronuclei
oocytes
%
Fertilization
Number of
embryos
transferred
Day of
embryo
transfer
Number
of sacs
1 8 7 88 3 43 2 2 1
2 12 6 50 5 83 4 2 1
3 9 7 78 2 29 2 2 0
4 7 3 43 3 100 3 3 2
5 20 18 90 16 89 4 3 NA
6 24 15 63 11 73 3 3 NA
7 16 12 75 10 83 2 6 NA
NA, The result of the b-hCG test is not available yet.
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P10: Effect of implementation of NICE guidelines on
BMI with regards to IVF/ICSI success rates
Grace Jose, Holly Kirwin, Katherine Maddocks, & Janet Evans
IVF Wales, UHW, Cardiff, United Kingdom
Introduction. NICE introduced a recommendation that women’s
BMI should be between 19 and 30 prior to commencing IVF for
optimal success rates and this was implemented in Wales by the
Welsh Assembly Government in June 2006 for all NHS patients.
This study aims to evaluate whether this change was associated
with any change in clinical pregnancy rates.
Material & Methods. A database was available with in the Cardiff
Assisted Reproduction Unit that enabled a comparison of clinical
pregnancies rates and BMI between data from 2005 and 2007
(excluding 2006 when the implementation began to be intro-
duced). Data regarding pregnancy rates and BMI was studied
from 2005 to 2007.
Results.
Conclusions. Implementation of the NICE guidelines was asso-
ciated with a dramatic improvement in pregnancy rates.
In a retrospective study such as this, other changes may be
happening simultaneously. In particular, non-smoking criteria,
and a reduction in the waiting time, making patients slightly
younger at the time of treatment, were also introduced by the
Welsh Assembly Government, and these factors, together with
laboratory changes, may have played a part in the improvement. A
more complete analysis of the data is planned looking at these
additional demographic factors.
P11: Spontaneous conception rates are increased during
monitored cycles in couples with a conception delay
S. Usman, Z. Sooky, D. White, & L. Webber
Imperial College Healthcare NHS Trust, London, United Kingdom
Measurement of the mid-luteal phase serum progesterone is a
standard fertility test to confirm that ovulation has occurred.
However, formal cycle monitoring with scans during the early
follicular phase, pre-ovulation and mid-luteal is educational for
patients and can help reveal subtle signs of reduced ovarian
reserve, such as dysfunctional follicular development. For some
couples, there is the additional benefit of knowing that ovulation is
imminent. Cycle monitoring is offered to all women with delayed
conception as a routine preliminary investigation in our unit. We
retrospectively audited the outcome of 61 monitored cycles and
compared pregnancy rates in the monitored cycle with that of the
subsequent five unmonitored cycles. (This study constituted an
audit of standard clinical practice and therefore did not require
ethical approval).
Methods. Consecutive natural cycles monitored between 1
January and 31 December 2006 were included in the study where
the outcome of the cycle was known, i.e. date of subsequent period
or result of a pregnancy test. The number of pregnancies occurring
over the next 5 months was recorded.
Results. Three hundred and seventy three cycle monitoring
records were assessed of which complete data was available on
61 women. Of these, 49 women ovulated and 12 did not. Seven
women conceived during the monitored cycle (14.3%) and four
women conceived over the next five cycles (10.2%, unmonitored
cycles). There was no difference in the mean age of the women
who conceived compared with those who did not (conceived:
mean age 35 years, range 29–41 years; not pregnant 35 years,
range 23–46 years).
Discussion. Formal cycle monitoring is a useful fertility investiga-
tion and may have an additional advantage of increasing
spontaneous conception rates, probably by encouraging inter-
course in the days leading up to ovulation.
P12: The optimal dose of human chorionic gonadotrophin
for final oocyte maturation and ovulation in
in vitro fertilization
Javaid A. Muglu1, Ioanna Tsoumpou2, Tarek A. Gelbaya3, &
Luciano G. Nardo4
1Department of Obstetrics and Gynaecology, St. Mary’s Hospital,
CMMC University Hospitals, Manchester, United Kingdom,
2Department of Obstetrics and Gynaecology, Royal Lancaster
Infirmary, Lancaster, United Kingdom, 3Department of Reproductive
Medicine, St. Mary’s Hospital, CMMC University Hospitals,
Manchester, United Kingdom, and 4Department of Reproductive
Medicine, St. Mary’s Hospital, CMMC University
Hospitals, Manchester, United Kingdom
Background. Although the human chorionic gonadotrophin
(hCG) has been established as the routine oocyte maturation
trigger in in vitro fertilization (IVF), there is no consensus over the
acceptable dose that should be used for final follicular maturation.
Objective. To identify the optimal dose of urinary hCG (u-hCG)
that can trigger final oocyte maturation and ovulation without
increasing the risk of ovarian hyperstimulation syndrome (OHSS).
Design. We conducted a systematic review considering all
controlled studies, both prospective and retrospective that assessed
the effect of at least two different doses of u-hCG administered for
final oocyte maturation, on IVF outcome and on the incidence of
hCG-related adverse effects. Both agonist and antagonist cycles
were considered.
The primary outcome was the live birth rate. The secondary
endpoints included the pregnancy and clinical pregnancy rate, the
numberofoocytes retrieved, the fertilizationand implantation rate and
the incidence of OHSS. All parameters were assessed as per patient.
Results. Amongst the six studies that met the inclusion criteria,
only two were randomized controlled trials (RCTs). The doses
compared were 2000, 3300, 5000, 10,000 and 15,000 IU of u-
hCG. Meta-analysis was not conducted due to the lack of
sufficient number of RCTs and heterogeneous variables in these
sparse studies. The majority of studies concluded that the clinical
outcomes are similar between women receiving 5000 compared
with 10,000 IU of u-hCG. However, only two studies commented
on the number of women who developed OHSS. The incidence of
OHSS was not eliminated in the high-risk population even with
lower dose of u-hCG.
Conclusions. There is no evidence that by reducing the dose of u-
hCG we significantly decrease the risk of OHSS. Until large-scale
RCTs that would assess not only both the clinical effectiveness but
also the adverse effects related to various doses of u-hCG are
conducted, the management of those women and especially of the
high-responders needs to be individualized.
P13: Empty follicular syndrome
Nikita Rawal & Rafet Gazvani
Liverpool Womens’ Hospital, Liverpool, United Kingdom
Recurrent EFS is a rare phenomenon, its impact very serious and
devastating for the patient.
We herein report a case of genuine ‘empty follicular syndrome’
in a woman in whom no oocytes was retrieved in three consecutive
IVF cycles. Our patient is a 28-year-old woman with primary
% Clinical pregnancy rates % Women BMI430
2005 14.9 16.9
2007 31.1 2.3
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unexplained subfertility of 5 years duration. She underwent three
IVF cycles using the long down-regulation protocol. In all three
cycles, apparently good ovarian response was observed. Prior to
egg collection, HCG was given at three different times in each
cycle (34, 32 and 36 h) and on each occasion, HCG was used from
three different batches. In spite of repeated flushing of all follicles
by an experienced operator, no oocytes were retrieved. The
woman also had an ovarian biopsy and chromosomal analysis,
which were normal.
Our case suggests that genuine EFS does exists. The possible
underlying cause of EFS in our case seems to be ovarian aging in
which the granulosa cells retain some responsiveness but oocyte
can no longer develop adequately. The report highlights the fact
that EFS cannot be predicted by the pattern of ovarian response to
super ovulation with endocrinology or sonographically. Conse-
quently, the diagnosis of EFS remains a retrospective one. There is
a great need to find out the cause of this puzzling condition and
possibly a way of predicting it.
P14: Optimisation of endometrial receptivity in
medicated frozen embryo replacement cycles.
The long proliferative phase revisited
Tarek El-Toukhy, Seth Kamal Sunkara, Helen Bickerstaff,
Ahmed Kamal, Yacoub Khalaf, & Peter Braude
Guy’s and St. Thomas’ Hospital NHS Foundation Trust,
London, United Kingdom
Background. Medicated frozen embryo replacement cycles
(FERCs) using oestrogen and progesterone supplementation
with or without prior pituitary down-regulation yield good results.
Objective. To examine the influence of the duration of oestrogen
supplementation on outcome of medicated FERCs with or
without pituitary down-regulation.
Methods. Analysis of 1124 cycles of medicated FERCs in which
oestrogen supplementation was started in 701 cycles after pituitary
down-regulation using buserelin nasal spray (group A) and in 423
cycles without prior pituitary down-regulation (group B). Cycles in
each group were subdivided depending on duration of oestrogen
supplementation given to achieve adequate endometrial thickness
(521 days and 21 days).
Results. In group A, the implantation, clinical pregnancy and
ongoing pregnancy/delivery rates remained similar in cycles where
oestrogen supplementation exceeded 20 days (n¼ 206) compared
with cycles where oestrogen supplementation was 20 days or less
(n¼495) [20.1% vs. 19.7%, P¼0.87; 29% vs. 28%, P¼0.85 and
26% vs. 23%, P¼ 0.47]. However, in group B, there was a
significant decline in the implantation, clinical pregnancy and
ongoing pregnancy/delivery rates when oestrogen supplementation
exceeded 20 days (n¼ 203) compared with cycles where oestrogen
supplementation was 20 days or less (n¼ 220) [10% vs. 17%,
P¼ 0.01; 16% vs. 26%, P¼ 0.03; 14% vs. 23%, P¼ 0.03,
respectively]. Multivariate logistic regression analysis showed that
extending the duration of oestrogen supplementation beyond 20
days was a significant factor affecting outcome in medicated
FERCs started without pituitary down-regulation (adjusted OR
0.53, 95% CI 0.32–0.89, P¼0.016).
Conclusion. Pituitary down-regulation prior to medicated FERCs
protects the endometrium from the effects of prolongation of the
proliferative phase beyond 20 days.
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